Cyclo Therapeutics Net Debt To E B I T D A Over Time
| CYTHW Stock | USD 0.13 0.01 7.14% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cyclo Therapeutics Performance and Cyclo Therapeutics Correlation. Cyclo |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Debt To E B I T D A Analysis
Compare Cyclo Therapeutics and related stocks such as Weyco Group, National Vision Holdings, and Meiwu Technology Net Debt To E B I T D A Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WEYS | (0.9468) | 0.9366 | 0.7887 | (0.121) | (0.2012) | 0.2617 | (0.3554) | (0.8304) | (0.5743) | 0.579 | 5.3364 | (0.2852) | 0.6706 | (1.2633) | (1.2) |
| EYE | 2.4536 | 2.4536 | 2.4536 | 2.4536 | 2.4536 | 7.6234 | 6.257 | 2.4536 | 2.4536 | 2.4536 | 2.4536 | 2.4536 | 4.7968 | 4.32 | 4.78 |
| WNW | (0.1297) | (0.1297) | (0.1297) | (0.1297) | (0.1297) | (0.1297) | (0.1297) | (0.1297) | (1.1965) | (0.9253) | 1.9563 | 26.3143 | 4.7553 | 10.566 | 11.09 |
| RDCM | (18.0516) | 1.7319 | (0.197) | 0.4653 | (2.1809) | 35.4756 | (30.4372) | (7.2079) | 21.8961 | (0.0041) | 2.7072 | 2.0208 | 1.9387 | (579) | (550) |
| GO | 8.2653 | 8.2653 | 8.2653 | 8.2653 | 8.2653 | 8.2653 | 8.2653 | 5.8712 | 6.4568 | 8.2653 | 8.2653 | 8.2653 | 7.5748 | 6.82 | 5.96 |
| ASUR | 0.1598 | 8.1084 | 10.0786 | 3.3802 | 3.3623 | 4.8114 | 3.568 | 9.5049 | 44.1326 | (0.1576) | 2.2248 | 1.1695 | 2.4976 | (1.2576) | (1.19) |
| AIHS | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | 0.8709 | 10.9079 | 3.8956 | (2.37) | (0.6174) | 0.0326 | 0.254 | 0.0245 | 0.0257 |
Cyclo Therapeutics and related stocks such as Weyco Group, National Vision Holdings, and Meiwu Technology Net Debt To E B I T D A description
A leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA).My Equities
My Current Equities and Potential Positions
| Cyclo Therapeutics | CYTHW |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Florida; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.13
Additional Tools for Cyclo Stock Analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.